Background: The primary goal of radiofrequency ablation (RFA) of atrial fibrillation (AF) is to improve symptoms and health-related quality of life (HRQoL). However, most studies have focused on predictors of AF recurrence rather than on predictors of improvement in symptoms and HRQoL.
in patients with AF) study. 3 It was conducted between January 2012 and April 2014. Patients referred for RFA because of AF to the University Hospital in Linköping, Sweden, were considered for participation. The inclusion criteria were: (a) age ≥ 18 years with paroxysmal or persistent AF, (b) Patients referred for first time RFA, and (c) patients with sufficient knowledge of the Swedish language to fill out the study questionnaires independently. Exclusion criteria were: (a previous catheter or surgical AF ablation, (b) previous or planned heart surgery, (c) left ventricular ejection fraction (EF) <35%, and (d) Acute coronary syndrome during the past 3 months.
| Informed consent and ethical considerations
The Regional Ethical Review Board of Linköping, Sweden, approved the study (Dnr 2011 (Dnr /40-31, 2012 . All patients gave their written consent and the study complied with the Declaration of Helsinki. 16 
| Study flow chart
The protocol of the SMURF study has been published previously by Charitakis et al. 17 In brief, enrolled patients were subjected to a full baseline evaluation including medical history, physical examination, 12-lead electrocardiography, and blood sampling. Transthoracic echocardiography (TTE) was performed the day before the RFA. All patients were catheterized according to the clinical routine, and additional blood samples were drawn. The ablation procedure has been described previously by Charitakis et al. 17 Patient-reported outcome measures (PROM) were assessed with three questionnaires, described in the following sections, at baseline, 1-month follow-up (FU) and
1-year FU.
| Echocardiography and laboratory tests
All patients underwent TTE prior to RFA. GE Vivid 7 or GE Vivid E9 system (GE Healthcare, Horten, Norway) were utilized. Left ventricular EF was calculated by the Simpson biplane method. Left atrial volume (LAV) was calculated as previously described Charitakis et al. 17 High sensitive C-reactive protein (hsCRP) was measured as previously described. 3 
| Recurrence of atrial fibrillation
AF recurrence was defined as a documented episode of AF or atrial flutter lasting more than 30 seconds, and/or the need for re-ablation, within 1 year from ablation date.
2.6 | Patient-reported outcome measures 2.7 | The medical outcomes study 36-item shortform health survey
The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) is a generic questionnaire comprising 36 items, of which 35 items evaluate eight scales ranging from 0 (worst possible health) to 100 (best possible health). 18 The eight scales are summarized in physical and mental component summaries, standardized to a norm with a mean of 50 and an SD of 10. 19 
| The arrhythmia-specific questionnaire in tachycardia and arrhythmia
The disease-specific questionnaire the arrhythmia-specific questionnaire in tachycardia and arrhythmia (ASTA) is a validated questionnaire and has been previously described in detail. 20, 21 In brief, nine items assess symptom burden (ASTA symptom scale) and 13 items assess HRQoL (ASTA HRQoL scale), all with a four-point response scale. 20, 21 The scale scores range from 0 to 100, where higher scores reflect a higher symptom burden and a worse effect on HRQoL, because of the arrhythmia. 20,21
| The hospital anxiety and depression scale
The domain-specific questionnaire hospital anxiety and depression scale (HADS) consists of two subscales, where seven items assess anxiety and seven assess depression. The score for each subscale ranges from 0 to 21. The scores are categorized as normal (0-7), possible, [8] [9] [10] and probable (≥11) anxiety and depression, respectively. 22 
| Statistics
Continuous normally distributed variables were expressed as means AE SD and non-normally distributed variables as medians with 25th to 75th percentiles within brackets. Categorical data were presented as counts with percentages within brackets.
In order to analyze possible predictors of improvement in arrhythmia-specific symptoms and HRQoL, the difference between the scores at 1-year FU and baseline were calculated for the ASTA symptom scale and the ASTA HRQoL scale, and used as the dependent variable in a simple linear regression analysis. The independent predictors used were: age, gender, body mass index, hypertension, heart failure, diabetes, AF type (paroxysmal or persistent), CHA 2 DS 2 -VASc score, AF episode duration (max AF episode duration of over 1 hour concerning the last 3 months before RFA), frequency of AF episodes (more than 10 episodes of AF the month before RFA), hsCRP, EF, LAV, AF recurrence, and finally possible and probable anxiety and depression as assessed with HADS. All variables that turned out to be significant were used in a multiple linear regression analysis, conducted in a stepwise backward elimination fashion. No statistical signs of multicollinearity were found in the final models.
Analysis of the change in all of the questionnaires summary scores, and in each item in ASTA, throughout the three measure points was performed with the Friedman test. In order to analyze between which time points there was a significant change, the Wilcoxon signed rank test was used between two measure points. The magnitude of the change between baseline and 1-year FU was assessed with effect size (ES), which was calculated and interpreted according to standard criteria where <0.20 denotes trivial, 0.20 to 0.49 small, 0.50 to 0.79 moderate, and ≥ 0.80 large ES. 4 All reported P-values were two-sided and a P-value <0.05 was considered statistically significant. The analyses were performed using the SPSS 24.0 (IBM, Armonk, New York).
| RESULTS

| Baseline characteristics
In total, 192 patients were included in the SMURF study. The baseline characteristics are presented in Table 1 . Missing PROM summary scores varied between 1% and 19%, 2% and 20%, and 4% and 18% for SF-36, ASTA and HADS, respectively, and were because of not returning the questionnaire or missing answers removing the possibility of calculating a summary score. Figure 1 shows the number of subjects included in the different analyses. There were no baseline differences between participants included in the study and those excluded because of logistical difficulties or because they declined participation. 23 3.2 | Predictors of improvement in arrhythmiaspecific symptoms and HRQoL
| Predictors of arrhythmia-specific symptoms
In the univariate analysis, female gender and >10 AF episodes in the last month before RFA were significant positive predictors, while diabetes and AF recurrence were significant negative predictors of improvement in ASTA symptom scale score between baseline and 1-year FU. In the multivariate analysis, these predictors remained significant ( Table 2 ).
| Predictors of arrhythmia-specific HRQoL
In the univariate analysis, >10 AF episodes in the last month before treatment, heart failure, probable anxiety, and probable depression were significant positive predictors, while diabetes, LAV, and AF recurrence were significant negative predictors of improvement in ASTA HRQoL scale score between baseline and 1-year FU ( Table 2 ).
In the multivariate analysis, probable anxiety and probable depression were no longer significant (Table 2 and Figure 2 ).
| The effect of catheter ablation on patientreported outcome measures
| Arrhythmia-specific symptoms
The most commonly reported symptoms, as assessed with ASTA, were breathlessness during activity, weakness/fatigue, and tiredness, while the least frequently reported symptom was chest pain (Supporting Information Figure S1 in the online version of this article).
Each item in the ASTA symptom scale improved significantly over time and there was a significant improvement in the ASTA symptom scale score with a large ES (Table 3 and Figure S1 ).
| Health-related quality of life
At baseline, the most commonly reported affected arrhythmia-specific HRQoL domains in ASTA were impaired physical activity, deteriorated life situation, the patient avoiding planning things s/he would have liked to do, and feeling unable to work, study or carry out daily activities ( Figure S2 ). All ASTA HRQoL items improved significantly over time ( Figure S2 ). The arrhythmia-specific HRQoL scale score improved significantly with a large ES (Table 3 ). General HRQoL, as assessed with SF-36, improved significantly with a small ES in all of the subscales ( Table 3) . 
| Anxiety and depression
The mean anxiety and depression scores at baseline, assessed with HADS, indicated normal levels of anxiety and depression (Table 3) . However, 55 (29%) had possible or probable anxiety and 33 (17%) had possible or probable depression. Both anxiety and depression mean scores improved significantly over time ( Table 3 ). The ES was trivial or small.
| DISCUSSION
In contrast to the most previous studies analyzing predictors of AF recurrence, this study analyzed predictors of improvement in symptoms and HRQoL. The most important predictors of improvement in both arrhythmia-specific symptoms and arrhythmia-specific HRQoL were freedom from AF recurrence, absence of diabetes and > 10 AF episodes in the month before RFA. In addition, female gender was a predictor for symptom improvement, while no dilated left atrium and the presence of heart failure were predictors for HRQoL improvement.
Furthermore, there was a large improvement in arrhythmiaspecific symptoms and arrhythmia-specific HRQoL, and a significant improvement in general HRQoL, anxiety and depression after first time RFA of AF.
| Predictors of improvement in arrhythmiaspecific symptoms and arrhythmia-specific HRQoL
The occurrence of frequent attacks of AF before RFA was a predictor of symptom and HRQoL improvement. In a study by Gaita in heart rate as an AF episode. 24 Hence, the patient might inaccurately recognize a persistent episode as more than one episode. Furthermore, classification of AF type can be simple in many patients, but The dependent variable was the scale score at the 1-year follow-up with the score at baseline subtracted. The independent predictors analyzed were: age, gender, body mass index (BMI), hypertension, heart failure, diabetes, AF type (paroxysmal or persistent), CHA 2 DS 2 -VASc score, AF episode duration (max AF episode duration of over 1 hour concerning the last 3 months before RFA), frequency of AF episodes (more than 10 episodes of AF the month before RFA), hsCRP, EF, LAV, AF recurrence, and finally possible and probable anxiety and depression as assessed with HADS. Variables that were significant in the univariate analysis were imputed in the multivariate analysis, which was conducted in a stepwise backward elimination fashion. Higher scores reflect a higher symptom burden and a worse HRQoL. The larger the improvement, the larger the decrease in ASTA-score. All reported P-values were two-sided and a P-value <0.05 was considered statistically significant. Summary scores are presented as medians (25th to 75th percentiles). ASTA and SF-36 scores range from 0 to 100 and HADS from 0 to 21. In SF-36, a higher score reflects better health status while the opposite is the case in ASTA and HADS. ES was calculated by dividing the mean difference between baseline and 1-year follow-up by the SD at baseline. A result <0.20 denotes trivial, 0.20-0.49 small, 0.50-0.79 moderate and ≥ 0.80 large ES. Analysis of development in questionnaire scores was performed using the Friedman test. Analysis of change between two time points was performed using Wilcoxon signed rank test. specific instrument, on the other hand, allows both the detection and reflection of disease-specific changes between patients with a specific disease and over time. Björkenheim et al. 4 showed that an arrhythmia-specific questionnaire is more sensitive to changes related to AF burden than a generic questionnaire and more accurately reflects the effect of RFA, indicating the importance of using a disease-specific instrument when evaluating the effects of RFA.
Hence, in this study, in which an arrhythmia-specific instrument was used, AF recurrence was one of the strongest inverse predictors of symptom and HRQoL improvement.
Diabetes was a negative predictor of both symptom and HRQoL improvement. In contrast to our study, Mohanty et al. 11 study, RFA for AF in patients with heart failure was associated with a significantly lower rate of the composite end point of death or hospitalization, and also with an improved EF and 6-minute walk test, compared to medical therapy. 25 Although the CASTLE-AF study only included patients with an EF < 35%, which was an exclusion criterion in the present study, the diagnosis of heart failure in our study was also associated with improvement after RFA. While reduced HRQoL in diabetic patients may be because of affection of several organs, cardiac dysfunction is most probably the primary cause of reduced HRQoL in heart failure patients. Restoring atrial function and thus improving cardiac function, consequently has a greater effect on HRQoL in patients with heart failure than in patients with diabetes.
LAV was a negative predictor of HRQoL improvement. LAV is a known predictor of AF recurrence post RFA, 26 and AF recurrence reduces the likelihood of improvement in HRQoL, especially when assessed by a disease-specific instrument. 4 However, although an arrhythmia-specific instrument was used in the present study, both LAV and AF recurrence remained as significant negative predictors of HRQoL improvement, indicating that larger LAV per se is negatively associated with HRQoL improvement. Larger LAV might be an indicator of more severe and longstanding AF, affecting HRQoL negatively, even after a successful RFA.
Female gender was a significant predictor of symptom improvement. In a previous study by Forleo et al, there was a trend towards a greater improvement in HRQoL, assessed with SF-36, in women compared to men, although not statistically significant. 27 The authors pointed out the small number of women in their study as a reason for the failure to detect a significant difference. Women are reported to have higher symptom burden and to be referred for RFA less often and later than men, despite that both men and women had equal results after RFA concerning clinical outcomes, such as treatment success rate, complications, AF recurrences, and hospitalizations. 27, 28 There are not any obvious explanations for these gender-related inequalities.
The predictors discussed above are not required in order for any improvement to occur and should rather be reviewed in relation to their counterpart. For example, men with ≤10 AF episodes the month before RFA may very well benefit from RFA, however, probably not as much as women with >10 AF episodes. Thus, the predictors do not have to be present in order for RFA to be meaningful. However, if they are, a greater improvement in symptoms and HRQoL can probably be expected, should these findings be confirmed in future studies.
|
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.2.1 | Arrhythmia-specific symptoms
As in the medical antiarrhythmic treatment or radiofrequency ablation in paroxysmal atrial fibrillation (MANTRA-PAF) trial, in which the ASTA questionnaire also was used, breathlessness during activity and tiredness were the most commonly reported symptoms. 29 After RFA, all the symptoms, as well as the ASTA symptom scale score, improved.
The large ES implies a large effect of RFA on symptom improvement, which is in line with other studies. [29] [30] [31] 
| Health-related quality of life
There was a large improvement in the disease-specific ASTA HRQoL score, which is in line with previous studies. 32 General HRQoL, assessed with SF-36, improved also, but to a lesser extent. The lesser degree of improvement was probably because of the above mentioned differences between generic and disease-specific instruments.
| Anxiety and depression
Anxiety and depression are common in patients with AF. 2 Thrall et al showed that approximately one-third of patients with AF have elevated levels of anxiety and depression, 2 as was the case for anxiety in the present study. Anxiety and depression are also known predictors of HRQoL, 2,3 and are associated with AF recurrence after RFA. 33 Although several possible mechanisms have been suggested, such as correlation with systemic inflammation and elevated sympathetic tone, 33 the mechanisms behind this relationship remain unclear. Both anxiety and depression improved after RFA, which is in line with previous studies. 33, 34 
| Limitations
One potential limitation to this study is that it is a single-center observational cohort study with a moderate sample size and no control group. Another is that it examined a heterogenic group of patients including people with both paroxysmal and persistent AF. Furthermore, the assessment of AF recurrence was made through examination of medical records and the local RFA register, and by 24-hour Holter monitoring. An implantable loop recorder could have been an alternative method, but was not within the scope of this study. Hence, the number of patients with AF recurrence was probably underestimated. Finally, the Friedman test requires valid scores at all measure points, which was not the case for all study participants.
| CONCLUSIONS
The most important predictors of improvement in arrhythmia-specific symptoms and HRQoL were frequent AF attacks before RFA, freedom from AF recurrence after RFA, and no diabetes, and additionally female gender for symptom improvement and heart failure and no enlarged left atrium for HRQoL improvement. Future studies are warranted to confirm these findings.
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